Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

PubWeight™: 1.01‹?› | Rank: Top 15%

🔗 View Article (PMC 3820000)

Published in Value Health on September 17, 2013

Authors

Jagpreet Chhatwal1, Shannon A Ferrante, Cliff Brass, Antoine C El Khoury, Margaret Burroughs, Bruce Bacon, Rafael Esteban-Mur, Elamin H Elbasha

Author Affiliations

1: Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Merck, Sharp, & Dohme Corp., Whitehouse Station, NJ, USA. Electronic address: chhatwal@pitt.edu.

Articles citing this

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07

Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology (2016) 0.95

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis (2015) 0.94

A systematic review of economic evaluations of treatments for borderline personality disorder. PLoS One (2014) 0.82

Why We Should Be Willing to Pay for Hepatitis C Treatment. Clin Gastroenterol Hepatol (2015) 0.79

Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther (2016) 0.79

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One (2016) 0.77

Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List. Hepatology (2016) 0.75

Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market. Croat Med J (2016) 0.75

An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes (2016) 0.75

Changing Cycle Lengths in State-Transition Models: Challenges and Solutions. Med Decis Making (2016) 0.75

Articles cited by this

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med (2012) 7.56

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53

Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med (1993) 5.32

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med (1999) 4.38

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making (2006) 3.50

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (1997) 3.10

Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90

Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2008 rates. Fed Regist (2007) 2.43

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43

Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09

Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96

Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology (1999) 1.90

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79

The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol (2008) 1.77

The epidemiology of hepatitis C infection in the United States. J Gastroenterol (2007) 1.71

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl (2010) 1.69

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol (2004) 1.68

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut (2003) 1.61

Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant (2010) 1.47

All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm (2011) 1.44

Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol (2011) 1.41

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35

A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC)• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results• Futility Rules in Telaprevir Combination Treatment• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim ResultsPLUS Meeting Abstract Summaries With Expert Commentary by: Jean-Pierre Bronowicki, MD, PhDDepartment of Hépato-GastroenterologieCentre Hospitalier Universitaire de Nancy-BraboisVandoeuvre-lès-Nancy, France. Gastroenterol Hepatol (N Y) (2012) 1.28

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess (2007) 1.19

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol (2010) 1.13

Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut (2001) 1.01

Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol (1997) 0.96

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol (2009) 0.91

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol (2013) 0.87

Articles by these authors

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16

Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2012) 2.02

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics (2005) 1.94

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol (2012) 1.71

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev (2006) 1.59

Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine (2011) 1.51

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis (2009) 1.35

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34

Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population. BMC Infect Dis (2011) 1.24

Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis (2012) 1.16

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev (2007) 1.11

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02

Burden of rotavirus gastroenteritis in the pediatric population in Central and Eastern Europe: serotype distribution and burden of illness. Hum Vaccin (2011) 1.02

Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. Hepatology (2007) 0.99

Drug therapy persistence and stroke recurrence. Am J Manag Care (2006) 0.98

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine (2007) 0.97

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag (2012) 0.95

Inequalities in self-reported physical health in the United States, 1993-1999. Health Econ (2005) 0.94

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93

The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol (2013) 0.91

The burden of rotavirus hospitalizations among Medicaid and non-Medicaid children younger than 5 years old. Am J Public Health (2009) 0.90

Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer (2007) 0.88

Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res (2008) 0.87

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ (2010) 0.84

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int (2013) 0.84

Vaccination and the evolutionary ecology of human papillomavirus. Vaccine (2008) 0.83

Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures? Health Econ (2003) 0.83

The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer. Math Biosci Eng (2013) 0.82

Burden of acute gastroenteritis among children younger than 5 years of age--a survey among parents in the United Arab Emirates. BMC Pediatr (2012) 0.81

Structural differences among cost-effectiveness models of human papillomavirus vaccines. Expert Rev Vaccines (2008) 0.81

Economics of stockpiling for an influenza pandemic. Lancet Infect Dis (2009) 0.80

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy (2013) 0.79

Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol (2012) 0.79

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev (2008) 0.78

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. Clinicoecon Outcomes Res (2012) 0.78

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. J Hepatol (2010) 0.78

Economic evaluation of the national immunization program of rotavirus vaccination for children in Korea. Asia Pac J Public Health (2012) 0.78

Cost-effectiveness of raltegravir in HIV/AIDS. Expert Rev Pharmacoecon Outcomes Res (2011) 0.78

Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan. J Med Econ (2011) 0.77

Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. J Clin Gastroenterol (2014) 0.77

Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore. Antivir Ther (2014) 0.76

Developing benchmarks for adherence studies. Expert Rev Pharmacoecon Outcomes Res (2005) 0.76

Prevalence of antibodies associated with herd immunity: a comment. Med Decis Making (2011) 0.75

Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection. Ann N Y Acad Sci (2013) 0.75

The decision to conduct a head-to-head comparative trial: a game-theoretic analysis. Med Decis Making (2007) 0.75